{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT03382912",
      "orgStudyIdInfo": {
        "id": "17161"
      },
      "secondaryIdInfos": [
        {
          "id": "J1L-AM-JZGD",
          "type": "OTHER",
          "domain": "Eli Lilly and Company"
        },
        {
          "id": "AM0010-202",
          "type": "OTHER",
          "domain": "ARMO BioSciences"
        }
      ],
      "organization": {
        "fullName": "Eli Lilly and Company",
        "class": "INDUSTRY"
      },
      "briefTitle": "Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer",
      "officialTitle": "A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1",
      "acronym": "Cypress 2"
    },
    "statusModule": {
      "statusVerifiedDate": "2020-06",
      "overallStatus": "TERMINATED",
      "whyStopped": "The CYPRESS-2 trial was closed early after the planned final analysis because the risk benefit ratio is unfavorable.",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2018-03-22",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2019-08-28",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2020-03-03",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2017-12-18",
      "studyFirstSubmitQcDate": "2017-12-21",
      "studyFirstPostDateStruct": {
        "date": "2017-12-26",
        "type": "ACTUAL"
      },
      "resultsFirstSubmitDate": "2020-08-22",
      "resultsFirstSubmitQcDate": "2020-08-22",
      "resultsFirstPostDateStruct": {
        "date": "2020-09-11",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2020-08-22",
      "lastUpdatePostDateStruct": {
        "date": "2020-09-11",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "Eli Lilly and Company",
        "class": "INDUSTRY"
      },
      "collaborators": [
        {
          "name": "ARMO BioSciences",
          "class": "INDUSTRY"
        }
      ]
    },
    "oversightModule": {
      "oversightHasDmc": false,
      "isFdaRegulatedDrug": true,
      "isFdaRegulatedDevice": false
    },
    "descriptionModule": {
      "briefSummary": "To compare the efficacy of pegilodecakin in combination with nivolumab versus nivolumab alone in participants with metastatic non-small cell lung cancer as measured by objective response rate.",
      "detailedDescription": "This is an open-label, multi-center, randomized, Phase 2 study designed to compare the efficacy and safety of pegilodecakin in combination with nivolumab versus nivolumab alone in participants with stage IV / metastatic wild type non-small cell lung cancer and tumors with low tumor expression of PD-L1 (0-49%)."
    },
    "conditionsModule": {
      "conditions": [
        "Non Small Cell Lung Cancer"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 52,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Pegilodecakin+Nivolumab",
          "type": "EXPERIMENTAL",
          "description": "Participants received Pegilodecakin subcutaneously at 0.8 milligrams (mg) (≤80 kilograms (kg) body weight) or 1.6 mg (\\>80 kg body weight) once daily (QD) in the abdomen, thigh or back of upper arm.\n\nNivolumab administered on day 1 of each 14 or 28 day cycle over approximately 30 minutes intravenous (IV) infusion at 240 mg every 2 weeks (Q2W), or 480 mg every 4 weeks (Q4W).",
          "interventionNames": [
            "Biological: Pegilodecakin",
            "Drug: Nivolumab"
          ]
        },
        {
          "label": "Nivolumab",
          "type": "ACTIVE_COMPARATOR",
          "description": "Participants received Nivolumab on day 1 of each 14- or 28- day cycle over approximately 30 minutes intravenous (IV) infusion at 240 mg every two weeks (Q2W), or 480 mg every 4 weeks (Q4W).",
          "interventionNames": [
            "Drug: Nivolumab"
          ]
        }
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "Pegilodecakin",
          "description": "Pegilodecakin plus Nivolumab",
          "armGroupLabels": [
            "Pegilodecakin+Nivolumab"
          ],
          "otherNames": [
            "LY3500518",
            "AM0010"
          ]
        },
        {
          "type": "DRUG",
          "name": "Nivolumab",
          "description": "Nivolumab Alone",
          "armGroupLabels": [
            "Nivolumab",
            "Pegilodecakin+Nivolumab"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]",
          "description": "Objective response rate is the best overall tumor response of complete response (CR) or partial response (PR) as classified by the independent central review according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions.",
          "timeFrame": "From Date of Randomization to Progressive Disease, Death from Any cause (Up to 6 months after the last participant randomized)"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Overall Survival (OS)",
          "description": "OS is defined as the time from first day of therapy to the date of death from any cause. Participants who were alive at the end of the follow-up period or were lost to follow-up, OS was censored on the last date the participant was known to be alive.",
          "timeFrame": "From Date of Randomization to Death Due to Any Cause (Up to 6 months after the last participant randomized)"
        },
        {
          "measure": "Progression Free Survival (PFS)",
          "description": "PFS is defined as the time from the day of randomization to the first evidence of progression as defined by Response Evaluation Criteria in Solid Tumors version 1.0 (RECIST v1.0) criteria or death from any cause. Progressive Disease (PD) is a 20% increase over the smallest sum of target lesions or new lesions. Participants who died without a reported prior disease progression were considered to have progressed on the day of their death. Participants who did not progress and were subsequently lost to follow-up had their data censored at the day of last tumor assessment.",
          "timeFrame": "From Date of Randomization to Progressive Disease or Death Due to Any Cause (Up to 6 months after the last participant randomized)"
        },
        {
          "measure": "Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD)",
          "description": "Disease control rate (DCR) is the percentage of participants with a best overall response of CR, PR or SD as defined by RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.",
          "timeFrame": "From Date of Randomization to Objective Progressive Disease or Start of New Anti-Cancer Therapy (Up to 6 Months after the last participant randomization)"
        },
        {
          "measure": "Duration of Response",
          "description": "Duration of response is defined as the time from the date measurement criteria for CR or PR (whichever is first recorded) are first met until the first date that disease is recurrent or objective progression is observed, per RECIST 1.1, or the date of death from any cause in the absence of objectively determined disease progression or recurrence. Participants known to be alive and without disease progression will be censored at the time of the last adequate tumor assessment.",
          "timeFrame": "From Date of Randomization to Death Due to Any Cause (Up to 6 months after the last participant randomized)"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n1. Participants must have histologically or cytologically confirmed Wild Type NSCLC that is stage IV / metastatic or recurrent\n2. Participants must have received at least one prior systemic therapy that was not an anti-PD-1, anti-PD-L1 and/or anti-CTLA-4 treatment for the advanced stage of the disease\n3. Participants with tumor tissue low expression of PD-L1 as defined by Tumor Proportion Score (TPS) 0% - 49%\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n5. Participants with measurable disease by spiral computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumor (RECIST) v.1.1 criteria\n6. Participants that have completed prior radiotherapy or radiosurgery at least 2 weeks prior to randomization\n\nExclusion Criteria:\n\n1. Participants with active central nervous system (CNS) metastases or carcinomatous meningitis\n2. Participants with any serious or uncontrolled medical disorder or active infection with the hepatitis virus or the human immunodeficiency virus (HIV)\n3. Participants with Grade 1 (NCI-CTCAE v.4.03) toxicities attributed to prior anti-cancer therapy (other than alopecia and fatigue) prior to randomization\n4. Participants that have received nivolumab\n5. Participants that have received therapy with anti-tumor vaccines or other immuno-stimulatory antitumor agents\n6. Participants with a history of severe hypersensitivity reactions to monoclonal antibodies\n7. Participants that have received therapy with anti-PD-1, anti-PD-L1, anti-PD-L-2, anti-CD-137, and/or anti CTLA-4 antibodies\n8. Participants receiving any investigational agent within 28 days of first administration of trial treatment\n9. Pregnant or lactating women",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)",
          "affiliation": "Eli Lilly and Company",
          "role": "STUDY_DIRECTOR"
        }
      ],
      "locations": [
        {
          "facility": "Arizona Oncology Associates, P.C.",
          "city": "Tempe",
          "state": "Arizona",
          "zip": "85284",
          "country": "United States",
          "geoPoint": {
            "lat": 33.41477,
            "lon": -111.90931
          }
        },
        {
          "facility": "Beverly Hills Cancer Center",
          "city": "Beverly Hills",
          "state": "California",
          "zip": "90211",
          "country": "United States",
          "geoPoint": {
            "lat": 34.07362,
            "lon": -118.40036
          }
        },
        {
          "facility": "Glendale Adventist Medical Center",
          "city": "Los Angeles",
          "state": "California",
          "zip": "90017",
          "country": "United States",
          "geoPoint": {
            "lat": 34.05223,
            "lon": -118.24368
          }
        },
        {
          "facility": "Redwood Regional Oncology Center",
          "city": "Santa Rosa",
          "state": "California",
          "zip": "95403",
          "country": "United States",
          "geoPoint": {
            "lat": 38.44047,
            "lon": -122.71443
          }
        },
        {
          "facility": "The Oncology Institute of Hope and Innovation",
          "city": "Whittier",
          "state": "California",
          "zip": "90602",
          "country": "United States",
          "geoPoint": {
            "lat": 33.97918,
            "lon": -118.03284
          }
        },
        {
          "facility": "Rocky Mountain Cancer Center",
          "city": "Lone Tree",
          "state": "Colorado",
          "zip": "80124",
          "country": "United States",
          "geoPoint": {
            "lat": 39.55171,
            "lon": -104.8863
          }
        },
        {
          "facility": "John B. Amos Cancer Center",
          "city": "Columbus",
          "state": "Georgia",
          "zip": "31904",
          "country": "United States",
          "geoPoint": {
            "lat": 32.46098,
            "lon": -84.98771
          }
        },
        {
          "facility": "Covenant Clinic",
          "city": "Waterloo",
          "state": "Iowa",
          "zip": "50702",
          "country": "United States",
          "geoPoint": {
            "lat": 42.49276,
            "lon": -92.34296
          }
        },
        {
          "facility": "Baptist Health Medical Group",
          "city": "Lexington",
          "state": "Kentucky",
          "zip": "40503",
          "country": "United States",
          "geoPoint": {
            "lat": 37.98869,
            "lon": -84.47772
          }
        },
        {
          "facility": "MedStar Health Research Institute",
          "city": "Baltimore",
          "state": "Maryland",
          "zip": "21237",
          "country": "United States",
          "geoPoint": {
            "lat": 39.29038,
            "lon": -76.61219
          }
        },
        {
          "facility": "Maryland Oncology Hematology, P.A.",
          "city": "Columbia",
          "state": "Maryland",
          "zip": "21044",
          "country": "United States",
          "geoPoint": {
            "lat": 39.24038,
            "lon": -76.83942
          }
        },
        {
          "facility": "Frederick Memorial Hospital",
          "city": "Frederick",
          "state": "Maryland",
          "zip": "21701",
          "country": "United States",
          "geoPoint": {
            "lat": 39.41427,
            "lon": -77.41054
          }
        },
        {
          "facility": "Sparrow Health System",
          "city": "Lansing",
          "state": "Michigan",
          "zip": "48912",
          "country": "United States",
          "geoPoint": {
            "lat": 42.73253,
            "lon": -84.55553
          }
        },
        {
          "facility": "Hattiesburg Clinic",
          "city": "Hattiesburg",
          "state": "Mississippi",
          "zip": "39401",
          "country": "United States",
          "geoPoint": {
            "lat": 31.32712,
            "lon": -89.29034
          }
        },
        {
          "facility": "The Valley Hospital - Luckow Pavilion",
          "city": "Westwood",
          "state": "New Jersey",
          "zip": "07675",
          "country": "United States",
          "geoPoint": {
            "lat": 40.99121,
            "lon": -74.03264
          }
        },
        {
          "facility": "Broome Oncology LLC",
          "city": "Johnson City",
          "state": "New York",
          "zip": "13790",
          "country": "United States",
          "geoPoint": {
            "lat": 42.11563,
            "lon": -75.95881
          }
        },
        {
          "facility": "Winthrop University Hospital",
          "city": "Mineola",
          "state": "New York",
          "zip": "11501",
          "country": "United States",
          "geoPoint": {
            "lat": 40.74927,
            "lon": -73.64068
          }
        },
        {
          "facility": "Clinical Research Alliance, Inc.",
          "city": "New Hyde Park",
          "state": "New York",
          "zip": "11042",
          "country": "United States",
          "geoPoint": {
            "lat": 40.7351,
            "lon": -73.68791
          }
        },
        {
          "facility": "Stony Brook University Medical Center",
          "city": "Stony Brook",
          "state": "New York",
          "zip": "11794",
          "country": "United States",
          "geoPoint": {
            "lat": 40.92565,
            "lon": -73.14094
          }
        },
        {
          "facility": "Gabrail Cancer Center",
          "city": "Canton",
          "state": "Ohio",
          "zip": "44718",
          "country": "United States",
          "geoPoint": {
            "lat": 40.79895,
            "lon": -81.37845
          }
        },
        {
          "facility": "Christ Hospital",
          "city": "Cincinnati",
          "state": "Ohio",
          "zip": "45219",
          "country": "United States",
          "geoPoint": {
            "lat": 39.12711,
            "lon": -84.51439
          }
        },
        {
          "facility": "University of Toledo Medical Center",
          "city": "Toledo",
          "state": "Ohio",
          "zip": "43614-2598",
          "country": "United States",
          "geoPoint": {
            "lat": 41.66394,
            "lon": -83.55521
          }
        },
        {
          "facility": "Charleston Hematology Oncology Associates",
          "city": "Charleston",
          "state": "South Carolina",
          "zip": "29414",
          "country": "United States",
          "geoPoint": {
            "lat": 32.77632,
            "lon": -79.93275
          }
        },
        {
          "facility": "Mamie McFaddin Ward Cancer Center",
          "city": "Beaumont",
          "state": "Texas",
          "zip": "77702",
          "country": "United States",
          "geoPoint": {
            "lat": 30.08605,
            "lon": -94.10185
          }
        },
        {
          "facility": "Texas Oncology - Dallas Presbyterian Hospital",
          "city": "Dallas",
          "state": "Texas",
          "zip": "75231",
          "country": "United States",
          "geoPoint": {
            "lat": 32.78306,
            "lon": -96.80667
          }
        },
        {
          "facility": "Texas Oncology-Baylor Charles A. Sammons Cancer Center",
          "city": "Dallas",
          "state": "Texas",
          "zip": "75246",
          "country": "United States",
          "geoPoint": {
            "lat": 32.78306,
            "lon": -96.80667
          }
        },
        {
          "facility": "Texas Oncology-Memorial City",
          "city": "Houston",
          "state": "Texas",
          "zip": "77024",
          "country": "United States",
          "geoPoint": {
            "lat": 29.76328,
            "lon": -95.36327
          }
        },
        {
          "facility": "Millennium Oncology",
          "city": "Houston",
          "state": "Texas",
          "zip": "77090",
          "country": "United States",
          "geoPoint": {
            "lat": 29.76328,
            "lon": -95.36327
          }
        },
        {
          "facility": "Joe Arrington Cancer Center",
          "city": "Lubbock",
          "state": "Texas",
          "zip": "79410",
          "country": "United States",
          "geoPoint": {
            "lat": 33.57786,
            "lon": -101.85517
          }
        },
        {
          "facility": "Texas Oncology - Midland Allison Cancer Center",
          "city": "Midland",
          "state": "Texas",
          "zip": "79701",
          "country": "United States",
          "geoPoint": {
            "lat": 31.99735,
            "lon": -102.07791
          }
        },
        {
          "facility": "US Oncology",
          "city": "The Woodlands",
          "state": "Texas",
          "zip": "77380",
          "country": "United States",
          "geoPoint": {
            "lat": 30.15799,
            "lon": -95.48938
          }
        },
        {
          "facility": "Texas Oncology - Tyler",
          "city": "Tyler",
          "state": "Texas",
          "zip": "75702",
          "country": "United States",
          "geoPoint": {
            "lat": 32.35126,
            "lon": -95.30106
          }
        },
        {
          "facility": "Fairfax Northern Virginia Hematology Oncology, PC",
          "city": "Fairfax",
          "state": "Virginia",
          "zip": "22031",
          "country": "United States",
          "geoPoint": {
            "lat": 38.84622,
            "lon": -77.30637
          }
        },
        {
          "facility": "Oncology and Hematology Associates of Southwest Virginia Inc",
          "city": "Roanoke",
          "state": "Virginia",
          "zip": "24014",
          "country": "United States",
          "geoPoint": {
            "lat": 37.27097,
            "lon": -79.94143
          }
        },
        {
          "facility": "MultiCare Regional Cancer Center - Auburn",
          "city": "Tacoma",
          "state": "Washington",
          "zip": "98002",
          "country": "United States",
          "geoPoint": {
            "lat": 47.25288,
            "lon": -122.44429
          }
        }
      ]
    },
    "referencesModule": {
      "references": [
        {
          "pmid": "33166722",
          "type": "DERIVED",
          "citation": "Spigel D, Jotte R, Nemunaitis J, Shum M, Schneider J, Goldschmidt J, Eisenstein J, Berz D, Seneviratne L, Socoteanu M, Bhanderi V, Konduri K, Xia M, Wang H, Hozak RR, Gueorguieva I, Ferry D, Gandhi L, Chao BH, Rybkin I. Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2). J Thorac Oncol. 2021 Feb;16(2):327-333. doi: 10.1016/j.jtho.2020.10.001. Epub 2020 Nov 6."
        },
        {
          "pmid": "32808556",
          "type": "DERIVED",
          "citation": "Albrethsen M, Creeden J, Morand S, DeBiase J, Berry B, Stanbery L, Edelman G, Nemunaitis J. Relationship of hypothyroidism and immune response to pegylated IL-10/nivolumab. Immunotherapy. 2020 Oct;12(14):1041-1046. doi: 10.2217/imt-2020-0016. Epub 2020 Aug 18."
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "YES",
      "description": "Yes\n\nAnonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.",
      "infoTypes": [
        "STUDY_PROTOCOL",
        "SAP",
        "CSR"
      ],
      "timeFrame": "Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.",
      "accessCriteria": "A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.",
      "url": "http://www.clinicalstudydatarequest.com"
    }
  },
  "resultsSection": {
    "participantFlowModule": {
      "preAssignmentDetails": "Completer's included participants who had progression free survival events (Progressive Disease (PD) or death).",
      "groups": [
        {
          "id": "FG000",
          "title": "Pegilodecakin+Nivolumab",
          "description": "Participants received Pegilodecakin subcutaneously at 0.8 milligrams (mg) (≤80 kilograms (kg) body weight) or 1.6 mg (\\>80 kg body weight) once daily (QD) in the abdomen, thigh or back of upper arm.\n\nNivolumab administered on day 1 of each 14 or 28 day cycle over approximately 30 minutes intravenous (IV) infusion at 240 mg every 2 weeks (Q2W), or 480 mg every 4 weeks (Q4W)."
        },
        {
          "id": "FG001",
          "title": "Nivolumab",
          "description": "Participants received Nivolumab on day 1 of each 14- or 28- day cycle over approximately 30 minutes intravenous (IV) infusion at 240 mg every two weeks (Q2W), or 480 mg every 4 weeks (Q4W)."
        }
      ],
      "periods": [
        {
          "title": "Overall Study",
          "milestones": [
            {
              "type": "STARTED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "27"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "25"
                }
              ]
            },
            {
              "type": "Received at Least 1 Dose of Study Drug",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "27"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "24"
                }
              ]
            },
            {
              "type": "COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "21"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "13"
                }
              ]
            },
            {
              "type": "NOT COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "6"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "12"
                }
              ]
            }
          ],
          "dropWithdraws": [
            {
              "type": "Physician Decision",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "1"
                }
              ]
            },
            {
              "type": "Sponsor Decision",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "6"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "6"
                }
              ]
            },
            {
              "type": "Withdrawal by Subject",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "5"
                }
              ]
            }
          ]
        }
      ]
    },
    "baselineCharacteristicsModule": {
      "populationDescription": "All randomized participants.",
      "groups": [
        {
          "id": "BG000",
          "title": "Pegilodecakin + Nivolumab",
          "description": "Participants received Pegilodecakin subcutaneously at 0.8 mg (≤80 kg body weight) or 1.6 mg (\\>80 kg body weight) once daily in the abdomen, thigh or back of upper arm.\n\nNivolumab administered on day 1 of each 14 or 28 day cycle over approximately 30 minutes IV infusion at 240 mg Q2W, or 480 mg Q4W."
        },
        {
          "id": "BG001",
          "title": "Nivolumab",
          "description": "Participants received Nivolumab on day 1 of each 14 or 28 day cycle over approximately 30 minutes IV infusion at 240 mg Q2W, or 480 mg Q4W."
        },
        {
          "id": "BG002",
          "title": "Total",
          "description": "Total of all reporting groups"
        }
      ],
      "denoms": [
        {
          "units": "Participants",
          "counts": [
            {
              "groupId": "BG000",
              "value": "27"
            },
            {
              "groupId": "BG001",
              "value": "25"
            },
            {
              "groupId": "BG002",
              "value": "52"
            }
          ]
        }
      ],
      "measures": [
        {
          "title": "Age, Continuous",
          "paramType": "MEAN",
          "dispersionType": "STANDARD_DEVIATION",
          "unitOfMeasure": "years",
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "68.4",
                      "spread": "8.2"
                    },
                    {
                      "groupId": "BG001",
                      "value": "65.9",
                      "spread": "10.4"
                    },
                    {
                      "groupId": "BG002",
                      "value": "67.2",
                      "spread": "9.3"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Sex: Female, Male",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "calculatePct": false,
          "classes": [
            {
              "categories": [
                {
                  "title": "Female",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "10"
                    },
                    {
                      "groupId": "BG001",
                      "value": "11"
                    },
                    {
                      "groupId": "BG002",
                      "value": "21"
                    }
                  ]
                },
                {
                  "title": "Male",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "17"
                    },
                    {
                      "groupId": "BG001",
                      "value": "14"
                    },
                    {
                      "groupId": "BG002",
                      "value": "31"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Ethnicity (NIH/OMB)",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "calculatePct": false,
          "classes": [
            {
              "categories": [
                {
                  "title": "Hispanic or Latino",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "2"
                    },
                    {
                      "groupId": "BG002",
                      "value": "2"
                    }
                  ]
                },
                {
                  "title": "Not Hispanic or Latino",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "24"
                    },
                    {
                      "groupId": "BG001",
                      "value": "20"
                    },
                    {
                      "groupId": "BG002",
                      "value": "44"
                    }
                  ]
                },
                {
                  "title": "Unknown or Not Reported",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "3"
                    },
                    {
                      "groupId": "BG001",
                      "value": "3"
                    },
                    {
                      "groupId": "BG002",
                      "value": "6"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Race (NIH/OMB)",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "calculatePct": false,
          "classes": [
            {
              "categories": [
                {
                  "title": "American Indian or Alaska Native",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Asian",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "1"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "1"
                    }
                  ]
                },
                {
                  "title": "Native Hawaiian or Other Pacific Islander",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Black or African American",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "1"
                    },
                    {
                      "groupId": "BG001",
                      "value": "3"
                    },
                    {
                      "groupId": "BG002",
                      "value": "4"
                    }
                  ]
                },
                {
                  "title": "White",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "23"
                    },
                    {
                      "groupId": "BG001",
                      "value": "20"
                    },
                    {
                      "groupId": "BG002",
                      "value": "43"
                    }
                  ]
                },
                {
                  "title": "More than one race",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Unknown or Not Reported",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "2"
                    },
                    {
                      "groupId": "BG001",
                      "value": "2"
                    },
                    {
                      "groupId": "BG002",
                      "value": "4"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Region of Enrollment",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "calculatePct": false,
          "classes": [
            {
              "title": "United States",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "27"
                    },
                    {
                      "groupId": "BG001",
                      "value": "25"
                    },
                    {
                      "groupId": "BG002",
                      "value": "52"
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "outcomeMeasuresModule": {
      "outcomeMeasures": [
        {
          "type": "PRIMARY",
          "title": "Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]",
          "description": "Objective response rate is the best overall tumor response of complete response (CR) or partial response (PR) as classified by the independent central review according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions.",
          "populationDescription": "All randomized participants.",
          "reportingStatus": "POSTED",
          "paramType": "NUMBER",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "Percentage of participants",
          "timeFrame": "From Date of Randomization to Progressive Disease, Death from Any cause (Up to 6 months after the last participant randomized)",
          "groups": [
            {
              "id": "OG000",
              "title": "Pegilodecakin + Nivolumab",
              "description": "Participants received Pegilodecakin subcutaneously at 0.8 mg (≤80 kg body weight) or 1.6 mg (\\>80 kg body weight) once daily in the abdomen, thigh or back of upper arm.\n\nNivolumab administered on day 1 of each 14 or 28 day cycle over approximately 30 minutes IV infusion at 240 mg Q2W or 480 mg Q4W."
            },
            {
              "id": "OG001",
              "title": "Nivolumab",
              "description": "Participants received Nivolumab on day 1 of each 14 or 28 day cycle over approximately 30 minutes IV infusion at 240 mg Q2W or 480 mg Q4W."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "27"
                },
                {
                  "groupId": "OG001",
                  "value": "25"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "14.8",
                      "lowerLimit": "4.2",
                      "upperLimit": "33.7"
                    },
                    {
                      "groupId": "OG001",
                      "value": "12.0",
                      "lowerLimit": "2.6",
                      "upperLimit": "31.2"
                    }
                  ]
                }
              ]
            }
          ],
          "analyses": [
            {
              "groupIds": [
                "OG000",
                "OG001"
              ],
              "nonInferiorityType": "SUPERIORITY",
              "paramType": "Odds Ratio (OR)",
              "paramValue": "1.2",
              "ciPctValue": "95",
              "ciNumSides": "TWO_SIDED",
              "ciLowerLimit": "0.3",
              "ciUpperLimit": "5.9",
              "estimateComment": "Odds Ratio stratified based on tumor histology at randomization (interactive web response system (IWRS)), smoking status (IWRS). Confidence intervals were based on the Clopper-Pearson method."
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Overall Survival (OS)",
          "description": "OS is defined as the time from first day of therapy to the date of death from any cause. Participants who were alive at the end of the follow-up period or were lost to follow-up, OS was censored on the last date the participant was known to be alive.",
          "populationDescription": "All randomized participants. Participants censored: Pegilodecakin + Nivolumab = 6 and Nivolumab = 5.",
          "reportingStatus": "POSTED",
          "paramType": "MEDIAN",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "Months",
          "timeFrame": "From Date of Randomization to Death Due to Any Cause (Up to 6 months after the last participant randomized)",
          "groups": [
            {
              "id": "OG000",
              "title": "Pegilodecakin + Nivolumab",
              "description": "Participants received Pegilodecakin subcutaneously at 0.8 mg (≤80 kg body weight) or 1.6 mg (\\>80 kg body weight) once daily in the abdomen, thigh or back of upper arm.\n\nNivolumab administered on day 1 of each 14 or 28 day cycle over approximately 30 minutes IV infusion at 240 mg Q2W or 480 mg Q4W."
            },
            {
              "id": "OG001",
              "title": "Nivolumab",
              "description": "Participants received Nivolumab on day 1 of each 14 or 28 day cycle over approximately 30 minutes IV infusion at 240 mg Q2W or 480 mg Q4W."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "27"
                },
                {
                  "groupId": "OG001",
                  "value": "25"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "1.87",
                      "lowerLimit": "1.51",
                      "upperLimit": "3.58"
                    },
                    {
                      "groupId": "OG001",
                      "value": "1.94",
                      "lowerLimit": "1.71",
                      "upperLimit": "2.17"
                    }
                  ]
                }
              ]
            }
          ],
          "analyses": [
            {
              "groupIds": [
                "OG000",
                "OG001"
              ],
              "nonInferiorityType": "SUPERIORITY",
              "paramType": "Hazard Ratio (HR)",
              "paramValue": "1.006",
              "ciPctValue": "95",
              "ciNumSides": "TWO_SIDED",
              "ciLowerLimit": "0.519",
              "ciUpperLimit": "1.951",
              "estimateComment": "The estimate of the hazard ration (HR) stratified based on tumor histology at randomization (interactive web response system (IWRS)) and smoking status (IWRS)."
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Progression Free Survival (PFS)",
          "description": "PFS is defined as the time from the day of randomization to the first evidence of progression as defined by Response Evaluation Criteria in Solid Tumors version 1.0 (RECIST v1.0) criteria or death from any cause. Progressive Disease (PD) is a 20% increase over the smallest sum of target lesions or new lesions. Participants who died without a reported prior disease progression were considered to have progressed on the day of their death. Participants who did not progress and were subsequently lost to follow-up had their data censored at the day of last tumor assessment.",
          "populationDescription": "All randomized participants. Participants censored: Pegilodecakin + Nivolumab = 12 and Nivolumab = 16.",
          "reportingStatus": "POSTED",
          "paramType": "MEDIAN",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "Months",
          "timeFrame": "From Date of Randomization to Progressive Disease or Death Due to Any Cause (Up to 6 months after the last participant randomized)",
          "groups": [
            {
              "id": "OG000",
              "title": "Pegilodecakin + Nivolumab",
              "description": "Participants received Pegilodecakin subcutaneously at 0.8 mg (≤80 kg body weight) or 1.6 mg (\\>80 kg body weight) once daily in the abdomen, thigh or back of upper arm.\n\nNivolumab administered on day 1 of each 14 or 28 day cycle over approximately 30 minutes IV infusion at 240 mg Q2W or 480 mg Q4W."
            },
            {
              "id": "OG001",
              "title": "Nivolumab",
              "description": "Participants received Nivolumab on day 1 of each 14 or 28 day cycle over approximately 30 minutes IV infusion at 240 mg Q2W or 480 mg Q4W."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "27"
                },
                {
                  "groupId": "OG001",
                  "value": "25"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "6.70",
                      "lowerLimit": "3.09",
                      "upperLimit": "NA",
                      "comment": "The upper 95% confidence interval was not achieved due to high censoring rate."
                    },
                    {
                      "groupId": "OG001",
                      "value": "10.74",
                      "lowerLimit": "4.21",
                      "upperLimit": "NA",
                      "comment": "The upper 95% confidence interval was not achieved due to high censoring rate."
                    }
                  ]
                }
              ]
            }
          ],
          "analyses": [
            {
              "groupIds": [
                "OG000",
                "OG001"
              ],
              "nonInferiorityType": "SUPERIORITY",
              "paramType": "Hazard Ratio (HR)",
              "paramValue": "1.871",
              "ciPctValue": "95",
              "ciNumSides": "TWO_SIDED",
              "ciLowerLimit": "0.772",
              "ciUpperLimit": "4.532",
              "otherAnalysisDescription": "The estimate of the hazard ration (HR) stratified based on tumor histology at randomization (IWRS) and smoking status (IWRS)."
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD)",
          "description": "Disease control rate (DCR) is the percentage of participants with a best overall response of CR, PR or SD as defined by RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.",
          "populationDescription": "All randomized participants.",
          "reportingStatus": "POSTED",
          "paramType": "NUMBER",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "Percentage of participants",
          "timeFrame": "From Date of Randomization to Objective Progressive Disease or Start of New Anti-Cancer Therapy (Up to 6 Months after the last participant randomization)",
          "groups": [
            {
              "id": "OG000",
              "title": "Pegilodecakin + Nivolumab",
              "description": "Participants received Pegilodecakin subcutaneously at 0.8 mg (≤80 kg body weight) or 1.6 mg (\\>80 kg body weight) once daily in the abdomen, thigh or back of upper arm.\n\nNivolumab administered on day 1 of each 14 or 28 day cycle over approximately 30 minutes IV infusion at 240 mg Q2W or 480 mg Q4W."
            },
            {
              "id": "OG001",
              "title": "Nivolumab",
              "description": "Participants received Nivolumab on day 1 of each 14 or 28 day cycle over approximately 30 minutes IV infusion at 240 mg Q2W or 480 mg Q4W."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "27"
                },
                {
                  "groupId": "OG001",
                  "value": "25"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "37.0",
                      "lowerLimit": "19.4",
                      "upperLimit": "57.6"
                    },
                    {
                      "groupId": "OG001",
                      "value": "28.0",
                      "lowerLimit": "12.1",
                      "upperLimit": "49.4"
                    }
                  ]
                }
              ]
            }
          ],
          "analyses": [
            {
              "groupIds": [
                "OG000",
                "OG001"
              ],
              "nonInferiorityType": "SUPERIORITY",
              "paramType": "Odds Ratio (OR)",
              "paramValue": "1.3",
              "ciPctValue": "95",
              "ciNumSides": "TWO_SIDED",
              "ciLowerLimit": "0.4",
              "ciUpperLimit": "4.1",
              "estimateComment": "Odds Ratio stratified based on tumor histology at randomization (IWRS) and smoking status (IWRS). Confidence intervals were based on the Clopper-Pearson method."
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Duration of Response",
          "description": "Duration of response is defined as the time from the date measurement criteria for CR or PR (whichever is first recorded) are first met until the first date that disease is recurrent or objective progression is observed, per RECIST 1.1, or the date of death from any cause in the absence of objectively determined disease progression or recurrence. Participants known to be alive and without disease progression will be censored at the time of the last adequate tumor assessment.",
          "populationDescription": "All randomized participants who received at least one dose of study drug and had CR or PR responses. Participants censored: Pegilodecakin + Nivolumab = 3 and Nivolumab = 1.",
          "reportingStatus": "POSTED",
          "paramType": "MEDIAN",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "Months",
          "timeFrame": "From Date of Randomization to Death Due to Any Cause (Up to 6 months after the last participant randomized)",
          "groups": [
            {
              "id": "OG000",
              "title": "Pegilodecakin + Nivolumab",
              "description": "Participants received Pegilodecakin subcutaneously at 0.8 mg (≤80 kg body weight) or 1.6 mg (\\>80 kg body weight) once daily in the abdomen, thigh or back of upper arm.\n\nNivolumab administered on day 1 of each 14 or 28 day cycle over approximately 30 minutes IV infusion at 240 mg Q2W or 480 mg Q4W."
            },
            {
              "id": "OG001",
              "title": "Nivolumab",
              "description": "Participants received Nivolumab on day 1 of each 14 or 28 day cycle over approximately 30 minutes IV infusion at 240 mg Q2W or 480 mg Q4W."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "4"
                },
                {
                  "groupId": "OG001",
                  "value": "3"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "NA",
                      "lowerLimit": "7.36",
                      "upperLimit": "NA",
                      "comment": "Median and the upper 95% confidence interval was not achieved due to high censoring rate."
                    },
                    {
                      "groupId": "OG001",
                      "value": "3.06",
                      "lowerLimit": "1.87",
                      "upperLimit": "NA",
                      "comment": "The upper 95% confidence interval was not achieved due to high censoring rate."
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "adverseEventsModule": {
      "frequencyThreshold": "5",
      "timeFrame": "Up to 23 Months",
      "description": "All randomized participants who received at least one dose of study drug. Gender specific events occurring only in male or female participants have had the number of participants at risk adjusted accordingly.",
      "eventGroups": [
        {
          "id": "EG000",
          "title": "Pegilodecakin + Nivolumab",
          "description": "Participants received Pegilodecakin subcutaneously at 0.8 mg (≤80 kg body weight) or 1.6 mg (\\>80 kg body weight) once daily in the abdomen, thigh or back of upper arm.\n\nNivolumab administered on day 1 of each 14 or 28 day cycle over approximately 30 minutes IV infusion at 240 mg Q2W or 480 mg Q4W.",
          "deathsNumAffected": 15,
          "deathsNumAtRisk": 27,
          "seriousNumAffected": 13,
          "seriousNumAtRisk": 27,
          "otherNumAffected": 27,
          "otherNumAtRisk": 27
        },
        {
          "id": "EG001",
          "title": "Nivolumab",
          "description": "Participants received Nivolumab on day 1 of each 14 or 28 day cycle over approximately 30 minutes IV infusion at 240 mg Q2W or 480 mg Q4W.",
          "deathsNumAffected": 12,
          "deathsNumAtRisk": 24,
          "seriousNumAffected": 9,
          "seriousNumAtRisk": 24,
          "otherNumAffected": 22,
          "otherNumAtRisk": 24
        }
      ],
      "seriousEvents": [
        {
          "term": "Anaemia",
          "organSystem": "Blood and lymphatic system disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 4,
              "numAffected": 4,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Haemolysis",
          "organSystem": "Blood and lymphatic system disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Thrombocytopenia",
          "organSystem": "Blood and lymphatic system disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Cardiac arrest",
          "organSystem": "Cardiac disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Cardio-respiratory arrest",
          "organSystem": "Cardiac disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Cardiomyopathy",
          "organSystem": "Cardiac disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Tachycardia",
          "organSystem": "Cardiac disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 1,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Bezoar",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Asthenia",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Pyrexia",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Pleural infection",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Pneumonia",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Rhinovirus infection",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Sepsis",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Streptococcal bacteraemia",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Fall",
          "organSystem": "Injury, poisoning and procedural complications",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Spinal fracture",
          "organSystem": "Injury, poisoning and procedural complications",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Dehydration",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Hyperkalaemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Bone neoplasm",
          "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Malignant pleural effusion",
          "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Tumour pain",
          "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Metabolic encephalopathy",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Syncope",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Mental status changes",
          "organSystem": "Psychiatric disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Acute kidney injury",
          "organSystem": "Renal and urinary disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Acute respiratory failure",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Bronchospasm",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Dyspnoea",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 4,
              "numAffected": 2,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Hypoxia",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Pleural effusion",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 1,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Respiratory failure",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Hypotension",
          "organSystem": "Vascular disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Superior vena cava syndrome",
          "organSystem": "Vascular disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 24
            }
          ]
        }
      ],
      "otherEvents": [
        {
          "term": "Anaemia",
          "organSystem": "Blood and lymphatic system disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 37,
              "numAffected": 14,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 24,
              "numAffected": 5,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Thrombocytopenia",
          "organSystem": "Blood and lymphatic system disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 15,
              "numAffected": 5,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 3,
              "numAffected": 2,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Atrial fibrillation",
          "organSystem": "Cardiac disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 5,
              "numAffected": 4,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Ear discomfort",
          "organSystem": "Ear and labyrinth disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Hypothyroidism",
          "organSystem": "Endocrine disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Abdominal pain",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 1,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Constipation",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 8,
              "numAffected": 7,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 5,
              "numAffected": 5,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Diarrhoea",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 3,
              "numAffected": 2,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 4,
              "numAffected": 3,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Dyspepsia",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Gastrooesophageal reflux disease",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Nausea",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 5,
              "numAffected": 4,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 7,
              "numAffected": 4,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Vomiting",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 6,
              "numAffected": 6,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Asthenia",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 9,
              "numAffected": 4,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Chills",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Fatigue",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 35,
              "numAffected": 17,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 18,
              "numAffected": 10,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Gait disturbance",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Influenza like illness",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Injection site rash",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 5,
              "numAffected": 5,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Oedema peripheral",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 11,
              "numAffected": 4,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Pain",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Pyrexia",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 14,
              "numAffected": 8,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 4,
              "numAffected": 4,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Pneumonia",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 3,
              "numAffected": 2,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Upper respiratory tract infection",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 1,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 3,
              "numAffected": 2,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Urinary tract infection",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 5,
              "numAffected": 3,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Vaginal infection",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 10
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 11
            }
          ]
        },
        {
          "term": "Fall",
          "organSystem": "Injury, poisoning and procedural complications",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 5,
              "numAffected": 3,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Alanine aminotransferase increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 4,
              "numAffected": 2,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Aspartate aminotransferase increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 6,
              "numAffected": 3,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Blood alkaline phosphatase increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 4,
              "numAffected": 2,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Blood bilirubin increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Blood creatinine increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 3,
              "numAffected": 2,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Blood thyroid stimulating hormone increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Platelet count decreased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 5,
              "numAffected": 4,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Troponin increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Weight decreased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 6,
              "numAffected": 5,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 6,
              "numAffected": 5,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Decreased appetite",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 12,
              "numAffected": 11,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 9,
              "numAffected": 7,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Dehydration",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 8,
              "numAffected": 6,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 5,
              "numAffected": 3,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Hyperglycaemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 8,
              "numAffected": 2,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 1,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Hypoalbuminaemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 4,
              "numAffected": 2,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Hypocalcaemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Hypokalaemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 7,
              "numAffected": 4,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 7,
              "numAffected": 4,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Hypomagnesaemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 4,
              "numAffected": 3,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Hypophosphataemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 3,
              "numAffected": 2,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Arthralgia",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 7,
              "numAffected": 5,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Back pain",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Groin pain",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 4,
              "numAffected": 2,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Muscular weakness",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Musculoskeletal chest pain",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 5,
              "numAffected": 3,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Musculoskeletal pain",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Pain in extremity",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Dizziness",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 10,
              "numAffected": 7,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 4,
              "numAffected": 4,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Dysgeusia",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 3,
              "numAffected": 2,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Headache",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 3,
              "numAffected": 2,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Anxiety",
          "organSystem": "Psychiatric disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 4,
              "numAffected": 3,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Depression",
          "organSystem": "Psychiatric disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Insomnia",
          "organSystem": "Psychiatric disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 4,
              "numAffected": 4,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Pollakiuria",
          "organSystem": "Renal and urinary disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Erectile dysfunction",
          "organSystem": "Reproductive system and breast disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 17
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Chronic obstructive pulmonary disease",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Cough",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 9,
              "numAffected": 8,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 5,
              "numAffected": 4,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Dysphonia",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Dyspnoea",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 18,
              "numAffected": 14,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 16,
              "numAffected": 10,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Haemoptysis",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 3,
              "numAffected": 2,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Hypoxia",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 4,
              "numAffected": 3,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Nasal congestion",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Oropharyngeal pain",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Pleural effusion",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Wheezing",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 3,
              "numAffected": 2,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Alopecia",
          "organSystem": "Skin and subcutaneous tissue disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Decubitus ulcer",
          "organSystem": "Skin and subcutaneous tissue disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 3,
              "numAffected": 2,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Pruritus",
          "organSystem": "Skin and subcutaneous tissue disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 7,
              "numAffected": 4,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 6,
              "numAffected": 5,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Rash",
          "organSystem": "Skin and subcutaneous tissue disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 5,
              "numAffected": 5,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 1,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Rash maculo-papular",
          "organSystem": "Skin and subcutaneous tissue disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 3,
              "numAffected": 2,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Rash pruritic",
          "organSystem": "Skin and subcutaneous tissue disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 3,
              "numAffected": 2,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 24
            }
          ]
        },
        {
          "term": "Hypotension",
          "organSystem": "Vascular disorders",
          "sourceVocabulary": "MedDRA 23.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 9,
              "numAffected": 7,
              "numAtRisk": 27
            },
            {
              "groupId": "EG001",
              "numEvents": 7,
              "numAffected": 6,
              "numAtRisk": 24
            }
          ]
        }
      ]
    },
    "moreInfoModule": {
      "certainAgreement": {
        "piSponsorEmployee": false,
        "restrictionType": "GT60",
        "restrictiveAgreement": true
      },
      "pointOfContact": {
        "title": "Chief Medical Officer",
        "organization": "Eli Lilly and Company",
        "email": "ClinicalTrials.gov@lilly.com",
        "phone": "800-545-5979"
      }
    }
  },
  "documentSection": {
    "largeDocumentModule": {
      "largeDocs": [
        {
          "typeAbbrev": "Prot",
          "hasProtocol": true,
          "hasSap": false,
          "hasIcf": false,
          "label": "Study Protocol",
          "date": "2019-02-06",
          "uploadDate": "2020-07-02T02:18",
          "filename": "Prot_000.pdf",
          "size": 3967343
        },
        {
          "typeAbbrev": "SAP",
          "hasProtocol": false,
          "hasSap": true,
          "hasIcf": false,
          "label": "Statistical Analysis Plan",
          "date": "2019-09-10",
          "uploadDate": "2020-07-02T02:21",
          "filename": "SAP_001.pdf",
          "size": 616666
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2025-10-28"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D002289",
          "term": "Carcinoma, Non-Small-Cell Lung"
        }
      ],
      "ancestors": [
        {
          "id": "D002283",
          "term": "Carcinoma, Bronchogenic"
        },
        {
          "id": "D001984",
          "term": "Bronchial Neoplasms"
        },
        {
          "id": "D008175",
          "term": "Lung Neoplasms"
        },
        {
          "id": "D012142",
          "term": "Respiratory Tract Neoplasms"
        },
        {
          "id": "D013899",
          "term": "Thoracic Neoplasms"
        },
        {
          "id": "D009371",
          "term": "Neoplasms by Site"
        },
        {
          "id": "D009369",
          "term": "Neoplasms"
        },
        {
          "id": "D008171",
          "term": "Lung Diseases"
        },
        {
          "id": "D012140",
          "term": "Respiratory Tract Diseases"
        }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "C000632591",
          "term": "pegilodecakin"
        },
        {
          "id": "C000622455",
          "term": "AM0010"
        },
        {
          "id": "D000077594",
          "term": "Nivolumab"
        }
      ],
      "ancestors": [
        {
          "id": "D061067",
          "term": "Antibodies, Monoclonal, Humanized"
        },
        {
          "id": "D000911",
          "term": "Antibodies, Monoclonal"
        },
        {
          "id": "D000906",
          "term": "Antibodies"
        },
        {
          "id": "D007136",
          "term": "Immunoglobulins"
        },
        {
          "id": "D007162",
          "term": "Immunoproteins"
        },
        {
          "id": "D001798",
          "term": "Blood Proteins"
        },
        {
          "id": "D011506",
          "term": "Proteins"
        },
        {
          "id": "D000602",
          "term": "Amino Acids, Peptides, and Proteins"
        },
        {
          "id": "D012712",
          "term": "Serum Globulins"
        },
        {
          "id": "D005916",
          "term": "Globulins"
        }
      ]
    }
  },
  "hasResults": true
}